Case series of the first three severe COVID-19 patients treated with the secretome of hypoxia-mesenchymal stem cells in Indonesia [version 3; peer review: 2 approved]

F1000Research

Basuki Rachmad¹  Fajar Amansyah²  Farid Amansyah²  Mukti Arja Berlian³  Agus Widyatmoko⁴  Retnaningsih Retnaningsih⁵  Flora Eka Sari⁶  Zenitalia Pasongka⁷  Agung Putra⁸  Sugeng Ibrahim⁸ 

[1] Department of Intensive Care Unit, Gatot Soebroto Army Hospital, Jakarta, Jakarta, Indonesia;Department of Internal Medicine, Bhayangkara Hospital, Makassar, South Sulawesi, Indonesia;Department of Internal Medicine, Dr. Esnawan Antariksa Air Force Hospital, Jakarta, Jakarta, Indonesia;Department of Internal Medicine, Faculty of Medicine, Universitas Muhammadiyah Yogyakarta, Yogyakarta, Yogyakarta, Indonesia;Department of Neurology and Intensive Care Unit, Kariadi Hospital, Universitas Diponegoro, Semarang, Central Java, Indonesia;Department of Pulmonary Medicine, Dr. Esnawan Antariksa Air Force Hospital, Jakarta, Jakarta, Indonesia;Faculty of Medicine, Universitas Udayana, Denpasar, Bali, Indonesia;Stem Cell and Cancer Research (SCCR), Faculty of Medicine, Universitas Islam Sultan Agung (Unissula), Semarang, Central Java, Indonesia;

关键词: COVID-19;    secretome;    mesenchymal stem cells;    eng;   

DOI  :  

来源: DOAJ

【 摘 要 】

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the outbreak of coronavirus disease 2019 (COVID-19), which has been rapidly spreading. Several guideline therapies have been proposed as a possible treatment for SARS-CoV-2, however, these therapies are not sufficient to treat a severe condition of SARS-CoV-2 infection characterised by the increase of D-dimer and C-reactive protein (CRP) levels, and patchy ground-glass opacities (GGOs). Secretome-mesenchymal stem cells (S-MSCs) produced by MSCs under hypoxia could excessively release several anti-inflammatory cytokines and growth factors to control the COVID-19 cytokine storm and accelerate lung injury improvement. This is the first study investigating the clinical outcomes of three severe COVID-19 patients admitted to the intensive care unit of three different hospitals in Indonesia treated with S-MSCs. The decrease of D-dimer and CRP level was reported for all patients treated with S-MSCs. This was in line with improvement of pulmonary radiology, blood gas level, and hematologic assessment. In conclusion, these cases suggest that S-MSCs could effectively control D-dimer, CRP level and GGOs of severe COVID-19 patients associated with recovered pulmonary function.

【 授权许可】

Unknown